nach oben

psychopraxis. neuropraxis

Erschienen in:

01.02.2017 | Psychiatrie

Aggression und serotoninerge Dysfunktion

Neurochemische Befunde und Therapiemöglichkeiten

verfasst von: Andreas Erfurth, Gabriele Sachs

Erschienen in: psychopraxis. neuropraxis | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aggression und Autoaggression sind ein alltägliches Problem in der psychiatrischen Praxis. In den vergangenen Jahren konnten zahlreiche Befunde erhoben werden, die auf eine serotoninerge Dysfunktion bei Aggression hindeuten. Ausgehend von diesen neurochemischen Ergebnissen werden therapeutische Ansätze mit serotoninergen Pharmaka vorgestellt und diskutiert.

Vorheriger Artikel Amyloid-PET und Alzheimer-Diagnose

Nächster Artikel Therapie depressiver Störungen mit selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI)

Rosell DR, Siever LJ (2015) The neurobiology of aggression and violence. CNS Spectr 20(3):254–279CrossRefPubMed

Blair RJ (2016) The neurobiology of impulsive aggression. J Child Adolesc Psychopharmacol 26(1):4–9CrossRefPubMedPubMedCentral

Beskow J, Gottfries CG, Roos BE, Winbald B (1976) Determination of monoamine and monoamine metabolites in the human brain: post mortem studies in a group of suicides and in a control group. Acta Psychiatr Scand 53:7–20CrossRefPubMed

Roy A, Karoum F, Pollack S (1992) Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiatry 49:447–450CrossRefPubMed

Erfurth A, Schmauß M (1990) Adenosin und Methylxanthine im Zentralnervensystem. Fortschr Neurol Psychiatr 58:137–147CrossRefPubMed

Coccaro EF, Fanning JR, Phan KL, Lee R (2015) Serotonin and impulsive aggression. CNS Spectr 20(3):295–302CrossRefPubMed

Glick AR (2015) The role of serotonin in impulsive aggression, suicide, and homicide in adolescents and adults: a literature review. Int J Adolesc Med Health 27(2):143–150CrossRefPubMed

Terranova JI, Song Z, Larkin TE 2nd, Hardcastle N, Norvelle A, Riaz A, Albers HE (2016) Serotonin and arginine-vasopressin mediate sex differences in the regulation of dominance and aggression by the social brain. Proc Natl Acad Sci USA 113(46):13233–13238. doi:10.1073/pnas.1610446113 CrossRefPubMedPubMedCentral

Tardiff K, Sweillam A (1980) Assault, suicide and mental illness. Arch Gen Psychiatry 37:164–169CrossRefPubMed

10.

Steinert T, Wolfersdorf M (1993) Aggression und Autoaggression. Psychiatr Prax 20:1–8PubMed

11.

Åsberg M, Träskman L, Thorèn P (1976) 5‑HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry 33:1193–1197CrossRefPubMed

12.

Åsberg M, Thorèn P, Träskman L, Bertilsson L, Ringberger V (1976) “Serotonin depression” – a biochemical subgroup within the affective disorders? Science 191:478–480CrossRefPubMed

13.

Träskman L, Åsberg M, Bertillson L, Thorèn P (1981) Monoamine metabolites in CSF and suicidal behaviour. Arch Gen Psychiatry 38:631–636CrossRefPubMed

14.

Greenberg AS, Coleman D (1976) Depressed 5‑hydroxyindole levels associated with hyperactivity and aggressive behaviour. Arch Gen Psychiatry 33:331–335CrossRefPubMed

15.

Cooper SJ, Kelly CB, King DJ (1992) 5‑Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. Lancet 340:940–941CrossRefPubMed

16.

Brown GL, Ballanger JC, Minichiello MD, Goodwin FK (1979) Human aggression and its relationship to cerebrospinal fluid 5‑hydroxyindoleacetic acid, 3‑methoxy-4 – hydroxyphenylglycol and homovanillic acid. In: Sandler M (Hrsg) Psychopharmacology of aggression. Raven, New York, S 131–148

17.

Gardner DL, Lucas PB, Cowdry RW (1990) CSF metabolites in borderline personality disorder compared with normal controls. Biol Psychiatry 28:247–254CrossRefPubMed

18.

Coccaro EF, Siever LJ, Klar H, Maurer GM, Cochrane K, Cooper TB, Mohs RC, Davis KL (1989) Serotonergic studies in affective and personality disorder patients: correlates with suicidal and impulsive aggression. Arch Gen Psychiatry 43:587–599CrossRef

19.

Linnoila M, Virkkunen M, Scheinin M et al (1983) Low cerebrospinal fluid 5‑HIAA concentration differentiates impulsive from non-impulsive violent behavior. Life Sci 33:2609–2614CrossRefPubMed

20.

Takahashi S, Yamane H, Kondo H et al (1974) CSF monoamine metabolites in alcoholism, a comparative study with depression. Folia Psychiatr Neurol Jpn 28:347–354PubMed

21.

Ballenger J, Goodwin F, Major L et al (1979) Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry 36:224–227CrossRefPubMed

22.

Lester D (1995) The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry 28:45–50CrossRefPubMed

23.

Mann JJ, Arango V (1992) Integration of neurobiology and psychopathology in a unified model of suicidal behavior. J Clin Psychopharmacol 12(Suppl):2–7

24.

Leyton M, Okazawa H, Diksic M, Paris J, Rosa P, Mzengeza S, Young SN, Blier P, Benkelfat C (2001) Brain Regional alpha-[11C]methyl-L-tryptophan trapping in impulsive subjects with borderline personality disorder. Am J Psychiatry 158(5):775–782CrossRefPubMed

25.

Frankle WG, Lombardo I, New AS, Goodman M, Talbot PS, Huang Y, Hwang DR, Slifstein M, Curry S, Abi-Dargham A, Laruelle M, Siever LJ (2005) Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. Am J Psychiatry 162(5):915–923CrossRefPubMed

26.

Koch W, Schaaff N, Pöpperl G, Mulert C, Juckel G, Reicherzer M, Ehmer-von Geiso C, Möller HJ, Hegerl U, Tatsch K, Pogarell O (2007) I‑123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. J Psychiatry Neurosci 32(4):234–240PubMedPubMedCentral

27.

Schmauß M, Erfurth A (1989) Indikationen für eine Therapie mit MAO-Hemmern. Psychiatr Prax 16(Sonderheft):2–6PubMed

28.

Moeller O, Hetzel G, Rothermundt M, Michael N, Nyhuis PW, Suslow T, Arolt V, Erfurth A (2003) Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment. J Psychiatr Res 37:261–262CrossRefPubMed

29.

Arentewicz G (1993) Evaluation einer stationären Kurzpsychotherapie für Patienten nach einem Suizidversuch. Habilitationsschrift. Medizinische Universität zu Lübeck, Lübeck

30.

Reimer C, Arentewicz G (1993) Kurzpsychotherapie nach Suizidversuch. Ein Leitfaden für die Praxis. Springer, BerlinCrossRef

31.

Wolfersdorf M (1992) Stellung von Psychopharmaka in der Behandlung von Suizidalität. Psychiatr Prax 19:100–107PubMed

32.

Tardiff K (1992) The current state of psychiatry in the treatment of violent patients. Arch Gen Psychiatry 49:493–499CrossRefPubMed

33.

Gardier AM, Kaakkola S, Erfurth A, Wurtman RJ (1992) Effects of methiothepin on changes in brain serotonin release induced by repeated administration of high doses of anorectic serotoninergic drugs. Brain Res 588:67–74CrossRefPubMed

34.

Erfurth A, Gardier AM, Ribeiro E, Wurtman RJ (1994) Effects of subchronic pretreatment with d‑fenfluramine or p‑chloroamphetamine on [3H]-inositolmonophosphate accumulation in rat cortical miniprisms. Brain Res 665:107–114CrossRefPubMed

35.

Müller-Oerlinghausen B (1989) Pharmakotherapie pathologischen aggressiven und autoaggressiven Verhaltens. In: Pöldinger W, Wagner W (Hrsg) Aggression, Selbstaggression, Familie und Gesellschaft. Springer, Berlin, S 121–134CrossRef

36.

Olivier B, Mos J, Raghoebar M, de Koning P, Mak M (1994) Serenics. Prog Drug Res 42:157–308

37.

de Boer SF, Koolhaas JM (2005) 5‑HT1A and 5‑HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol 526(1–3):125–139CrossRefPubMed

38.

Deberdt R (1976) Pipamperone in the treatment of behavior disorders. Acta Psychiatr Belg 79:157–166

39.

Inman WH (1988) Blood disorders and suicide in patients taking mianserin or amitriptyline. Lancet 2(8602):90–92CrossRefPubMed

40.

Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ (2001) A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 11(3):267–277CrossRefPubMed

41.

Montgomery SA, McAuley R, Rani SJ, Roy D, Montgomery DB (1981) A double blind comparison of zimeldine and amitriptyline in endogenous depression. Acta Psychiatr Scand 63(Suppl 290):314–327CrossRef

42.

Amin MM, Anath JV, Coleman BS et al (1984) Fluvoxamine antidepressant effects confirmed in a placebo controlled international study. Clin Neuropharmacol 7(Suppl 1):580–581

43.

Muijen M, Roy D, Silverstone F, Mehmet A, Christie M (1988) A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand 78:384–390CrossRefPubMed

44.

Beasley CM, Dornseif BE, Bosomworth JC (1991) Fluoxetine and suicide: a metaanalysis of controlled trials of treatment for depression. Brit Med J 303:685–692CrossRefPubMedPubMedCentral

45.

Möller HJ, Steinmeyer EM (1994) Are serotonergic reuptake inhibitors more potent in reducing suicidality? Eur Neuropsychopharmacol 4:55–59CrossRefPubMed

46.

Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15(1):23–29CrossRefPubMed

47.

Coccaro EF, Lee RJ, Kavoussi RJ (2009) A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 70(5):653–662CrossRefPubMed

48.

Silva H, Iturra P, Solari A, Villarroel J, Jerez S, Jiménez M, Galleguillos F, Bustamante ML (2010) Fluoxetine response in impulsive-aggressive behavior and serotonin transporter polymorphism in personality disorder. Psychiatr Genet 20(1):25–30CrossRefPubMed

49.

George DT, Phillips MJ, Lifshitz M, Lionetti TA, Spero DE, Ghassemzedeh N, Doty L, Umhau JC, Rawlings RR (2011) Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study. J Clin Psychiatry 72(1):60–65CrossRefPubMed

50.

Coccaro EF, Sripada CS, Yanowitch RN, Phan KL (2011) Corticolimbic function in impulsive aggressive behavior. Biol Psychiatry 69(12):1153–1159CrossRefPubMed

51.

Felthous AR, Stanford MS (2015) A proposed algorithm for the pharmacotherapy of impulsive aggression. J Am Acad Psychiatry Law 43(4):456–467PubMed

52.

Wakelin JS (1988) The role of serotonin in depression and suicide: do serotonin reuptake inhibitors provide a key? In: Mendlewicz JH, van Praag M (Hrsg) Advances in biological psychiatry, Bd. 17. Karger, Basel, S 70–83

53.

Sacchetti E, Vita A, Guarneri L, Cornacchia M (1991) The effectiveness of fluoxetine, clomipramine, nortriptyline and desipramine in major depressives with suicidal behaviour: preliminary findings. In: Cassano GB, Akiskal HS (Hrsg) Serotonin-related psychiatric syndromes: clinical and therapeutic links. Royal Society of Medicine services international congress and symposium series, Bd. 165. Royal Society of Medicine, London, S 47–53

54.

Teicher MH, Glod C, Cole JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147:207–210CrossRefPubMed

55.

Möller HJ (1992) Antidepressants – do they decrease or increase suicidality? Pharmacopsychiatry 25:249–253CrossRefPubMed

56.

Brewerton TD (1991) Fluoxetine – induced suicidality, serotonin and seasonality. Biol Psychiatry 30:190–196CrossRefPubMed

57.

Kasper S, Möller HJ (1995) Antidepressive Psychopharmakotherapie. Dtsch Ärztebl 92(7):A428–A434

58.

Sharma T, Guski LS, Freund N, Gøtzsche PC (2016) Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 352:i65CrossRefPubMedPubMedCentral

59.

Ho D (2012) Antidepressants and the FDA’s black-box warning: determining a rational public policy in the absence of sufficient evidence. Virtual Mentor 14(6):483–488CrossRefPubMed

60.

Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Marusic A, Mehlum L, Patton G, Phillips M, Rutz W, Rihmer Z, Schmidtke A, Shaffer D, Silverman M, Takahashi Y, Varnik A, Wasserman D, Yip P, Hendin H (2005) Suicide prevention strategies: a systematic review. JAMA 294(16):2064–2074CrossRefPubMed

61.

Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2006) The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 163(11):1898–1904CrossRefPubMed

62.

Rihmer Z, Akiskal H (2006) Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 94(1–3):3–13CrossRefPubMed

63.

Hall WD, Lucke J (2006) How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality? Aust N Z J Psychiatry 40:941–950CrossRefPubMed

64.

Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297(15):1683–1696CrossRefPubMed

65.

Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S (2015) Selective serotonin reuptake inhibitors and violent crime: a cohort study. PLOS Med 12(9):e1001875CrossRefPubMedPubMedCentral

66.

Whitaker KJ, Vértes PE, Romero-Garcia R, Váša F, Moutoussis M, Prabhu G, Weiskopf N, Callaghan MF, Wagstyl K, Rittman T, Tait R, Ooi C, Suckling J, Inkster B, Fonagy P, Dolan RJ, Jones PB, Goodyer IM, NSPN Consortium, Bullmore ET (2016) Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome. Proc Natl Acad Sci USA 113(32):9105–9110CrossRefPubMedPubMedCentral

67.

Kelvin AS, Hakansson S (1989) Comparative acute toxicity of paroxetine and other antidepressants. Acta Psychiatr Scand 80(Suppl 350):31–33CrossRef

68.

Boyer WF, Blunhardt CL (1992) The safety profile of paroxetine. J Clin Psychiatry 53(Suppl):61–66PubMed

69.

Dechant KL, Clissold SP (1991) Paroxetine. Drugs 41:225–253CrossRefPubMed

70.

de Jonghe F, Swinkels JA (1992) The safety of antidepressants. Drugs 43(Suppl 2):40–47CrossRefPubMed

71.

Schmauß M, Erfurth A (1993) Prädiktion des antidepressiven Behandlungserfolges – kritische Übersicht und Perspektiven. Fortschr Neurol Psychiatr 61:274–283CrossRefPubMed

72.

Bioulac B, Benezich M, Renaud B, Noel B, Roche D (1980) Serotonergic function in the 47-XXY syndrome. Biol Psychiatry 15:917–923PubMed

Titel: Aggression und serotoninerge Dysfunktion
Neurochemische Befunde und Therapiemöglichkeiten
verfasst von: Andreas Erfurth
Gabriele Sachs
Publikationsdatum: 01.02.2017
Verlag: Springer Vienna
Erschienen in: psychopraxis. neuropraxis / Ausgabe 1/2017
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI: https://doi.org/10.1007/s00739-016-0366-2

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Diagnostik und Therapie des Morbus Parkinson

aktuell

Panorama

Amyloid-PET und Alzheimer-Diagnose

Inzidentelle Befunde vaskulärer Ätiologie in der kranialen MRT

Wie sieht die Versorgungsrealität in Österreich für Patienten mit komplexem Behandlungs- und Betreuungsbedarf aus?